Immunogen Inc. Stock
Immunogen Inc. Stock
So far the community has only identified positive things for Immunogen Inc. stock. The most positive votes were given for criterium "Worthwhile Investment for the next years".
Pros and Cons of Immunogen Inc. in the next few years
Pros
?
S********** s********
?
M***** P*******
?
G***** c******* t* c**********
Cons
?
B****
?
W********* I********* f** t** n*** y****
?
C******** o* t** e**********
Tell us your opinion to access the 'Wisdom of the Crowds'
Performance of Immunogen Inc. vs. its peers
| Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
|---|---|---|---|---|---|---|---|
| Immunogen Inc. | - | - | - | - | - | - | - |
| Ardelyx Inc. | 3.710% | 0.436% | -11.361% | 47.951% | 3.668% | -1.770% | - |
| Salarius Pharmaceuticals Inc. | -2.830% | -4.072% | 0.000% | -70.556% | -23.604% | -98.430% | -99.993% |
| Brainstorm Cell | -30.000% | -29.447% | -33.143% | -87.283% | 51.293% | -87.897% | - |
Comments
ImmunoGen, Inc. (NASDAQ: IMGN) is now covered by analysts at Deutsche Bank Aktiengesellschaft. They set a "buy" rating and a $25.00 price target on the stock.
Show more
Ratings data for IMGN provided by MarketBeat
ImmunoGen, Inc. (NASDAQ: IMGN) was upgraded by analysts at JPMorgan Chase & Co. from a "neutral" rating to an "overweight" rating. They now have a $22.00 price target on the stock, up previously from $9.00.
Show more
Ratings data for IMGN provided by MarketBeat
ImmunoGen, Inc. (NASDAQ: IMGN) had its price target raised by analysts at HC Wainwright from $26.00 to $27.00. They now have a "buy" rating on the stock.
Show more
Ratings data for IMGN provided by MarketBeat
News
Why Abbvie Stock Popped Today
The big asset buy in the healthcare industry provided a healthy pop to the two companies involved on Thursday. The stock price of the buyer, sector mainstay AbbVie (NYSE: ABBV), enjoyed a nearly 3%
